These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 32402633)

  • 1. Clonal tumor mutations in homologous recombination genes predict favorable clinical outcome in ovarian cancer treated with platinum-based chemotherapy.
    Luo S; Zhang Y; Yang Y; Zhu S; Liu W; Zhu J; Liang X; Jiang Z; Sun S; Hou X; Xiao Y; Li X
    Gynecol Oncol; 2020 Jul; 158(1):66-76. PubMed ID: 32402633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study.
    Norquist BM; Brady MF; Harrell MI; Walsh T; Lee MK; Gulsuner S; Bernards SS; Casadei S; Burger RA; Tewari KS; Backes F; Mannel RS; Glaser G; Bailey C; Rubin S; Soper J; Lankes HA; Ramirez NC; King MC; Birrer MJ; Swisher EM
    Clin Cancer Res; 2018 Feb; 24(4):777-783. PubMed ID: 29191972
    [No Abstract]   [Full Text] [Related]  

  • 3. Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations.
    Jean S; Li J; Katsaros D; Wubbenhorst B; Maxwell KN; Fishbein L; McLane MW; Benedetto C; Canuto EM; Mitra N; Zhang L; Nathanson KL; Tanyi JL
    Oncotarget; 2016 Jul; 7(30):48577-48585. PubMed ID: 27191893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of homologous recombination repair pathway genes mutation in ovarian cancers.
    Yi Z; Chen M; Sun S; Yang C; Mei Z; Yang H; Xiang Q; Qiu H
    Cancer Innov; 2022 Oct; 1(3):220-228. PubMed ID: 38089758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
    Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W
    JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy.
    Kang J; D'Andrea AD; Kozono D
    J Natl Cancer Inst; 2012 May; 104(9):670-81. PubMed ID: 22505474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients.
    Tumiati M; Hietanen S; Hynninen J; Pietilä E; Färkkilä A; Kaipio K; Roering P; Huhtinen K; Alkodsi A; Li Y; Lehtonen R; Erkan EP; Tuominen MM; Lehti K; Hautaniemi SK; Vähärautio A; Grénman S; Carpén O; Kauppi L
    Clin Cancer Res; 2018 Sep; 24(18):4482-4493. PubMed ID: 29858219
    [No Abstract]   [Full Text] [Related]  

  • 8. Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes.
    da Costa AABA; do Canto LM; Larsen SJ; Ribeiro ARG; Stecca CE; Petersen AH; Aagaard MM; de Brot L; Baumbach J; Baiocchi G; Achatz MI; Rogatto SR
    BMC Cancer; 2019 May; 19(1):422. PubMed ID: 31060523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma.
    Feng Z; Shao D; Cai Y; Bi R; Ju X; Chen D; Song C; Chen X; Li J; An N; Li Y; Zhou Q; Xiu Z; Zhu S; Wu X; Wen H
    J Ovarian Res; 2023 Mar; 16(1):53. PubMed ID: 36922847
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Mirza MR; Lindahl G; Mahner S; Redondo A; Fabbro M; Rimel BJ; Herrstedt J; Oza AM; Canzler U; Berek JS; González-Martín A; Follana P; Lord R; Azodi M; Estenson K; Wang Z; Li Y; Gupta D; Matulonis U; Feng B
    Cancer Res Commun; 2022 Nov; 2(11):1436-1444. PubMed ID: 36970052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.
    Pennington KP; Walsh T; Harrell MI; Lee MK; Pennil CC; Rendi MH; Thornton A; Norquist BM; Casadei S; Nord AS; Agnew KJ; Pritchard CC; Scroggins S; Garcia RL; King MC; Swisher EM
    Clin Cancer Res; 2014 Feb; 20(3):764-75. PubMed ID: 24240112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing.
    Zhao Q; Yang J; Li L; Cao D; Yu M; Shen K;
    J Gynecol Oncol; 2017 Jul; 28(4):e39. PubMed ID: 28541631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between gene expression and mutator phenotype predicts homologous recombination deficiency and outcome in ovarian cancer.
    Lu J; Wu D; Li C; Zhou M; Hao D
    J Mol Med (Berl); 2014 Nov; 92(11):1159-68. PubMed ID: 25062964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer.
    Bookman MA; Tyczynski JE; Espirito JL; Wilson TW; Fernandes AW
    Gynecol Oncol; 2017 Jul; 146(1):58-63. PubMed ID: 28454659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homologous recombination and DNA repair mutations in patients treated with carboplatin and nab-paclitaxel for metastatic non-small cell lung cancer.
    Owen DH; Williams TM; Bertino EM; Mo X; Webb A; Schweitzer C; Liu T; Roychowdhury S; Timmers CD; Otterson GA
    Lung Cancer; 2019 Aug; 134():167-173. PubMed ID: 31319977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients.
    Rodriguez-Freixinos V; Fariñas-Madrid L; Gil-Martin M; Barretina-Ginesta P; Romeo M; Villacampa G; Pardo B; Ahmed H; Recalde S; Piulats JM; Gómez-Plaza MC; Gil-Moreno A; Sala E; Martínez-Román S; Ponce J; Meléndez C; Carballas E; Dienstmann R; Oaknin A
    Gynecol Oncol; 2019 Feb; 152(2):270-277. PubMed ID: 30551885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Application value of DNA damage repair variants in adjuvant therapy of triple negative breast cancer].
    Wang X; Yue J; Kang YK; Gao SL; Yuan P
    Zhonghua Zhong Liu Za Zhi; 2023 Sep; 45(9):787-795. PubMed ID: 37805443
    [No Abstract]   [Full Text] [Related]  

  • 18. BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin.
    Safra T; Borgato L; Nicoletto MO; Rolnitzky L; Pelles-Avraham S; Geva R; Donach ME; Curtin J; Novetsky A; Grenader T; Lai WC; Gabizon A; Boyd L; Muggia F
    Mol Cancer Ther; 2011 Oct; 10(10):2000-7. PubMed ID: 21835933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatic hypermutation and outcomes of platinum based chemotherapy in patients with high grade serous ovarian cancer.
    Sohn I; Jung WY; Sung CO
    Gynecol Oncol; 2012 Jul; 126(1):103-8. PubMed ID: 22484402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A genomic instability score in discriminating nonequivalent outcomes of BRCA1/2 mutations and in predicting outcomes of ovarian cancer treated with platinum-based chemotherapy.
    Zhang S; Yuan Y; Hao D
    PLoS One; 2014; 9(12):e113169. PubMed ID: 25437005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.